# Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

> **NCT00920972** · PHASE1,PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 220 (estimated)

## Conditions studied

- Metabolic Disorders
- Hematologic, Immune, or Bone Marrow Disorders
- Hemoglobinopathies
- Non-malignant Disorders

## Interventions

- **DRUG:** Treatment Plan 1: Stratum 1
- **DRUG:** Treatment Plan 2: Strata 2, 3, or 4
- **DRUG:** GVHD Regimen A: UCB Recipients
- **DRUG:** GVHD Regimen B: BM Recipients

## Key facts

- **NCT ID:** NCT00920972
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2001-12
- **Primary completion:** 2026-12
- **Final completion:** 2031-12
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00920972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00920972, "Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00920972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*